HilleVax, Inc.
HLVX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2 | $2 | $0 |
| Gross Profit | $0 | -$2 | -$2 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $78 | $107 | $46 | $10 |
| G&A Expenses | $29 | $27 | $17 | $6 |
| SG&A Expenses | $29 | $27 | $17 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $48 | $0 | -$95 | $0 |
| Operating Expenses | $155 | $133 | $63 | $16 |
| Operating Income | -$155 | -$133 | -$65 | -$53 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8 | $10 | -$95 | -$49 |
| Pre-Tax Income | -$147 | -$124 | -$160 | -$102 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$147 | -$124 | -$257 | -$85 |
| % Margin | – | – | – | – |
| EPS | -3 | -3.04 | -6.83 | -2.82 |
| % Growth | 1.3% | 55.5% | -142.2% | – |
| EPS Diluted | -3 | -3.04 | -6.83 | -2.82 |
| Weighted Avg Shares Out | 49 | 41 | 38 | 30 |
| Weighted Avg Shares Out Dil | 49 | 41 | 38 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $10 | $4 | $0 |
| Interest Expense | -$3 | $2 | $3 | $3 |
| Depreciation & Amortization | $0 | $1 | $2 | $0 |
| EBITDA | -$155 | -$132 | -$65 | -$100 |
| % Margin | – | – | – | – |